Table 2.
Patient and disease characteristics at the time of stereotactic body radiation therapy
| Characteristic | Patient (n=66) | Lesion (n=81) |
|---|---|---|
| Overall PSA (ng/mL), median (range) | 1.9 (0–32) | 1.9 (0–32) |
| PSA (ng/mL), n (%) | ||
| 0–5 | 51 (77.3) | 60 (74.1) |
| >5–10 | 9 (13.6) | 12 (14.8) |
| >10–20 | 5 (7.6) | 8 (9.9) |
| >20 | 1 (1.5) | 1 (1.2) |
| Total no. of metastases, no. of patients (%) | ||
| 1 | 46 (69.7) | 52 (64.2) |
| 2 | 12 (18.2) | 18 (22.2) |
| 3 | 3 (4.5) | 4 (4.9) |
| 4 | 1 (1.5) | 1 (1.2) |
| 5 | 2 (3.0) | 4 (4.9) |
| 6–10 | 0 (0) | 0 (0) |
| >10 | 2 (3.0) | 2 (2.5) |
| Regions treated, n (%) | ||
| Bone | ||
| Thoracic spine | 7 (10.6) | 9 (11.1) |
| Lumbar spine | 9 (13.6) | 10 (12.3) |
| Sacrum | 13 (19.7) | 16 (19.8) |
| Pelvis | 21 (31.8) | 24 (29.6) |
| Sternum | 3 (4.5) | 4 (4.9) |
| Rib | 5 (7.6) | 8 (9.9) |
| Acromion | 2 (3.0) | 2 (2.5) |
| Scapula | 1 (1.5) | 1 (1.2) |
| Lymph node | 5 (7.6) | 6 (7.4) |
| Liver | 1 (1.5) | 1 (1.2) |
| Primary indication, n (%) | ||
| Definitive | 57 (86.4) | 69 (85.2) |
| Palliative | 9 (13.6) | 12 (14.8) |
Abbreviation as in Table 1.